K858 50mg | ≥99%
CSNpharm
K858 is a selective and ATP-uncompetitive mitotic kinesin Eg5 inhibitor with IC50 value of 1.3 μM.
More Information Supplier Page
K858 is a selective and ATP-uncompetitive mitotic kinesin Eg5 inhibitor with IC50 value of 1.3 μM.
More Information Supplier Page
K858 is a selective and ATP-uncompetitive mitotic kinesin Eg5 inhibitor with IC50 value of 1.3 μM.
More Information Supplier Page
K858 is a selective and ATP-uncompetitive mitotic kinesin Eg5 inhibitor with IC50 value of 1.3 μM.
More Information Supplier Page
Pramiracetam is a nootropic drug derived from piracetam, and is more potent. Pramiracetam reportedly improved cognitive deficits associated with traumatic brain injuries.
More Information Supplier Page
LDN-57444 is a reversible inhibitor of UCHL1 with IC50 of 0.88 μM (Ki = 0.4 μM) and its selectivity is better than UCH-L3 (IC50 = 25 μM).
More Information Supplier Page
LDN-57444 is a reversible inhibitor of UCHL1 with IC50 of 0.88 μM (Ki = 0.4 μM) and its selectivity is better than UCH-L3 (IC50 = 25 μM).
More Information Supplier Page
LDN-57444 is a reversible inhibitor of UCHL1 with IC50 of 0.88 μM (Ki = 0.4 μM) and its selectivity is better than UCH-L3 (IC50 = 25 μM).
More Information Supplier Page
LDN-57444 is a reversible inhibitor of UCHL1 with IC50 of 0.88 μM (Ki = 0.4 μM) and its selectivity is better than UCH-L3 (IC50 = 25 μM).
More Information Supplier Page
Pramiracetam is a nootropic drug derived from piracetam, and is more potent. Pramiracetam reportedly improved cognitive deficits associated with traumatic brain injuries.
More Information Supplier Page
Pramiracetam is a nootropic drug derived from piracetam, and is more potent. Pramiracetam reportedly improved cognitive deficits associated with traumatic brain injuries.
More Information Supplier Page